Nuveen Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2024
Q4 | $5.74M | Sell |
434,058
-25,474
| -6% | -$337K | ﹤0.01% | 1920 |
|
2024
Q3 | $8.85M | Sell |
459,532
-96,882
| -17% | -$1.86M | ﹤0.01% | 1688 |
|
2024
Q2 | $11.4M | Buy |
556,414
+163,728
| +42% | +$3.36M | ﹤0.01% | 1501 |
|
2024
Q1 | $9.35M | Sell |
392,686
-231,324
| -37% | -$5.51M | ﹤0.01% | 1636 |
|
2023
Q4 | $13.5M | Buy |
624,010
+450,571
| +260% | +$9.74M | ﹤0.01% | 1396 |
|
2023
Q3 | $2.52M | Buy |
173,439
+12,492
| +8% | +$181K | ﹤0.01% | 2207 |
|
2023
Q2 | $3.37M | Buy |
160,947
+9,710
| +6% | +$203K | ﹤0.01% | 2098 |
|
2023
Q1 | $3.19M | Buy |
151,237
+6,375
| +4% | +$135K | ﹤0.01% | 2131 |
|
2022
Q4 | $3.69M | Sell |
144,862
-21,015
| -13% | -$535K | ﹤0.01% | 2087 |
|
2022
Q3 | $3.99M | Buy |
165,877
+35
| +0% | +$841 | ﹤0.01% | 2030 |
|
2022
Q2 | $3.19M | Buy |
165,842
+2,252
| +1% | +$43.3K | ﹤0.01% | 2195 |
|
2022
Q1 | $2.77M | Sell |
163,590
-271
| -0.2% | -$4.59K | ﹤0.01% | 2364 |
|
2021
Q4 | $2.93M | Sell |
163,861
-10,809
| -6% | -$193K | ﹤0.01% | 2379 |
|
2021
Q3 | $3.46M | Sell |
174,670
-42,244
| -19% | -$836K | ﹤0.01% | 2415 |
|
2021
Q2 | $3.73M | Buy |
216,914
+78,723
| +57% | +$1.35M | ﹤0.01% | 2396 |
|
2021
Q1 | $3.09M | Sell |
138,191
-18,147
| -12% | -$406K | ﹤0.01% | 2407 |
|
2020
Q4 | $3.48M | Sell |
156,338
-30,303
| -16% | -$674K | ﹤0.01% | 2250 |
|
2020
Q3 | $2.76M | Buy |
186,641
+69,338
| +59% | +$1.02M | ﹤0.01% | 2223 |
|
2020
Q2 | $1.74M | Buy |
117,303
+42,266
| +56% | +$627K | ﹤0.01% | 2400 |
|
2020
Q1 | $824K | Sell |
75,037
-14,119
| -16% | -$155K | ﹤0.01% | 2596 |
|
2019
Q4 | $783K | Sell |
89,156
-59,832
| -40% | -$525K | ﹤0.01% | 2773 |
|
2019
Q3 | $1.11M | Buy |
148,988
+39,756
| +36% | +$297K | ﹤0.01% | 2656 |
|
2019
Q2 | $1.02M | Buy |
+109,232
| New | +$1.02M | ﹤0.01% | 2727 |
|